바이오스펙테이터

by Jongwon Jang

The first two Biomarkers based on Blood enabled early diagnosis of Acute Coronary Syndrome (ACS), such as Acute Myocardial Infarction and Unstable Angina Pectoris.

This is the key source technology of the bio-venture ACS Diagnostics (ACS), founded in November 2018 by Dr. Kim Jie-wan (CEO) and Professor Kang Sang-won (CTO) (Ehwa Women’s University, Department of Life Science). ACS developed the primary strategy aiming for the approval of the product that would enable early diagnosis using these biomarkers. The development of a diagnostic kit for acute coronary syndrome will be followed by a therapeutic (preventive) agent, as well as the prediction of immunological rejection of internal organs by allograft.

Acute coronary syndromes, such as atherosclerosis owing to vascular occlusions, are critical diseases by which the patients would die shortly; however the rapid and convenient early diagnosis of such disease is not easy. These diseases have been diagnosed through CT, MRI, and cardiography examinations, requiring significant expense and time, and necessitating the visit of patients who are suffering from chest pain to hospitals.

ACS discovered and verified two strong biomarkers in blood that are capable of solving these problems, acquired patent rights in Korea, and filed patent applications in countries such as Australia, China, Europe, Japan, and the United States of America. IL-12R2 and PDGFR are the biomarkers, which were found from exosome originated from dedifferentiated smooth muscle cell, which is found from the initial process of acute coronary syndrome.... <계속>